Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation

被引:4
作者
Uno, Yasuhiro [1 ,4 ]
Uehara, Shotaro [2 ]
Ushirozako, Genki [1 ]
Murayama, Norie [3 ]
Suemizu, Hiroshi [2 ]
Yamazaki, Hiroshi [3 ]
机构
[1] Kagoshima Univ, Joint Fac Vet Med, Kagoshima, Japan
[2] Cent Inst Expt Anim, Dept Appl Res Lab Anim, 3-25-12 Tonomachi,Kawasaki Ku, Kawasaki 2100821, Japan
[3] Showa Pharmaceut Univ, Lab Drug Metab & Pharmacokinet, 3-3165 Higashi Tamagawa Gakuen, Machida, Tokyo 1948543, Japan
[4] Kagoshima Univ, Joint Fac Vet Med, 1-21-24 Korimoto, Kagoshima, Kagoshima 8900065, Japan
关键词
induction; omeprazole; 5-hydroxylation; dog liver; HUMAN LIVER; INDUCTION; OXIDATION; P450; 3A; METABOLISM; INDUCERS; CYP1A1; CYP3A; 2D6;
D O I
10.1080/00498254.2023.2266840
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The induction assay for the cytochromes P450 (P450s) is an important tool in drug discovery and development. The inductions of dog P450 1A2 and 3A12 by omeprazole and rifampicin were functionally characterised in dog hepatocytes and were compared with induction in human HepaRG and HepaSH cells.P450 1A2-dependent ethoxyresorufin O-deethylation was induced by R,S-omeprazole and P450 3 A-dependent midazolam 1 '-hydroxylation was induced by rifampicin, and both reactions were significantly enhanced in cultured dog hepatocytes and human HepaRG and HepaSH cells.Recombinant dog P450 1A2 exhibited activities towards R- and S-omeprazole 5-hydroxylation with low Km values of 23-28 mu M, whereas dog P450 2C21 and 3A12 efficiently mediated S-omeprazole 5-hydroxylation and sulfoxidation, respectively, with high Vmax values of 12-17 min-1.Although omeprazole 5-hydroxylation by human P450 2C19 (and sulfoxidation by P450 3A4) in human HepaSH cells were slightly (similar to 2-fold) induced by R,S-omeprazole, dog P450 1A2 was autoinduced by omeprazole in dog hepatocytes and showed enhanced R-omeprazole 5-hydroxylation activity (similar to 5-fold).These results indicate that omeprazole can be an autoinducer of P450 1A2 in hepatocytes, and this enzyme was found to be involved in omeprazole 5-hydroxylation and sulfoxidation in dog hepatocytes and human HepaRG and HepaSH cells.
引用
收藏
页码:465 / 473
页数:9
相关论文
共 31 条
  • [1] Äbelö A, 2000, DRUG METAB DISPOS, V28, P966
  • [2] Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells
    Antherieu, Sebastien
    Chesne, Christophe
    Li, Ruoya
    Camus, Sandrine
    Lahoz, Agustin
    Picazo, Laura
    Turpeinen, Miia
    Tolonen, Ari
    Uusitalo, Jouko
    Guguen-Guillouzo, Christiane
    Guillouzo, Andre
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (03) : 516 - 525
  • [3] Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail"
    Chainuvati, S
    Nafziger, AN
    Leeder, JS
    Gaedigk, A
    Kearns, GL
    Sellers, E
    Zhang, YH
    Kashuba, ADM
    Rowland, E
    Bertino, JS
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) : 437 - 447
  • [4] CURIPEDROSA R, 1994, J PHARMACOL EXP THER, V269, P384
  • [5] OMEPRAZOLE, AN INDUCER OF HUMAN CYP1A1 AND 1A2, IS NOT A LIGAND FOR THE AH RECEPTOR
    DAUJAT, M
    PERYT, B
    LESCA, P
    FOURTANIER, G
    DOMERGUE, J
    MAUREL, P
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 188 (02) : 820 - 825
  • [6] Ferguson MJ, 2017, DRUG HEALTHC PATIENT, V9, P89, DOI 10.2147/DHPS.S140213
  • [7] Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes
    Graham, RA
    Tyler, LO
    Krol, WL
    Silver, IS
    Webster, LO
    Clark, P
    Chen, LF
    Banks, T
    LeCluyse, EL
    [J]. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2006, 20 (02) : 69 - 78
  • [8] In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs
    Graham, RA
    Downey, A
    Mudra, D
    Krueger, L
    Carroll, K
    Chengelis, C
    Madan, A
    Parkinson, A
    [J]. DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) : 1206 - 1213
  • [9] New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
    Huang, Shiew-Mei
    Strong, John M.
    Zhang, Lei
    Reynolds, Kellie S.
    Nallani, Srikanth
    Temple, Robert
    Abraham, Sophia
    Al Habet, Sayed
    Baweja, Raman K.
    Burckart, Gilbert J.
    Chung, Sang
    Colangelo, Philip
    Frucht, David
    Green, Martin D.
    Hepp, Paul
    Karnaukhova, Elena
    Ko, Hon-Sum
    Lee, Jang-Ik
    Marroum, Patrick J.
    Norden, Janet M.
    Qiu, Wei
    Rahman, Atiqur
    Sobel, Solomon
    Stifano, Toni
    Thummel, Kenneth
    Wei, Xiao-Xiong
    Yasuda, Sally
    Zheng, Jenny H.
    Zhao, Hong
    Lesko, Lawrence J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (06) : 662 - 670
  • [10] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
    Li-Wan-Po, Alain
    Girard, Thierry
    Farndon, Peter
    Cooley, Candy
    Lithgow, James
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (03) : 222 - 230